Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Q635415
| Molecular Weight | 569.6 g/mol |
|---|---|
| Molecular Formula | C24H35N5O11 |
| XLogP3 | -7.1 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 19 |
| Exact Mass | 569.23330695 g/mol |
| Monoisotopic Mass | 569.23330695 g/mol |
| Topological Polar Surface Area | 237 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 862 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Ibritumomab Tiuxetan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibritumomab Tiuxetan, including repackagers and relabelers. The FDA regulates Ibritumomab Tiuxetan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibritumomab Tiuxetan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ibritumomab Tiuxetan supplier is an individual or a company that provides Ibritumomab Tiuxetan active pharmaceutical ingredient (API) or Ibritumomab Tiuxetan finished formulations upon request. The Ibritumomab Tiuxetan suppliers may include Ibritumomab Tiuxetan API manufacturers, exporters, distributors and traders.
Ibritumomab Tiuxetan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ibritumomab Tiuxetan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ibritumomab Tiuxetan GMP manufacturer or Ibritumomab Tiuxetan GMP API supplier for your needs.
A Ibritumomab Tiuxetan CoA (Certificate of Analysis) is a formal document that attests to Ibritumomab Tiuxetan's compliance with Ibritumomab Tiuxetan specifications and serves as a tool for batch-level quality control.
Ibritumomab Tiuxetan CoA mostly includes findings from lab analyses of a specific batch. For each Ibritumomab Tiuxetan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ibritumomab Tiuxetan may be tested according to a variety of international standards, such as European Pharmacopoeia (Ibritumomab Tiuxetan EP), Ibritumomab Tiuxetan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ibritumomab Tiuxetan USP).
LOOKING FOR A SUPPLIER?
